SEC Company Response from NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — May 20, 2020
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: May 20, 2020 · CIK: 0001389545 · Accession: 0001437749-20-011359
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238317
Letter
Re: NovaBay Pharmaceuticals, Inc. (the “Company”)
nby20200520_corresp.htm
May 20, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Form S-1, File No. 333-238317
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective as of 5:00 p.m. (Eastern time) on Friday, May 22, 2020, or as soon as practicable thereafter.
Very truly yours,
NovaBay Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm nby20200520_corresp.htm May 20, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: NovaBay Pharmaceuticals, Inc. (the “Company”) Form S-1, File No. 333-238317 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective as of 5:00 p.m. (Eastern time) on Friday, May 22, 2020, or as soon as practicable thereafter. Very truly yours, NovaBay Pharmaceuticals, Inc. By: /s/ Justin Hall Justin Hall President & Chief Executive Officer and General Counsel cc: Abby E. Brown, Squire Patton Boggs (US) LLP